Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Group leaders in the Departments of Biochemistry (Profs Christina Redfield, Jason Schnell and John Vakonakis) and Chemistry (Profs. Andy Baldwin and Tim Claridge) have secured support towards upgrading the flagship 950 MHz nuclear magnetic resonance (NMR) spectrometer, housed in Biochemistry.

Funding of close to £500K has been obtained from the Engineering and Physical Sciences Research Council (EPSRC) under the “Very- and Ultra-High field NMR for the physical and life sciences” initiative. The 950 MHz NMR upgrade will include a high-sensitivity 5mm TCI “CryoProbe” and an automated sample changer. This new probe will increase 1H signal-to-noise by a factor of up to 3, allowing more challenging macromolecular systems to be studied. The sample changer will improve throughput by enabling fully automated, round-the-clock data collection. Once upgraded, time on the 950 MHz NMR spectrometer will also be made available to external users from other UK academic institutions and from industry. 

Find out more (Department of Biochemistry website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.